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ABSTRACT 
Head and neck squamous cell carcinomas rarely cause cranial metastases, but HPV 
related subgroup is known for unusual metastasis sites on the body. Despite the 
good overall treatment responses in this group, intracranial metastases are always 
accepted as a sign of rapid deterioration. We present a case of cranium metastasis of 
HPV related oropharyngeal squamous cell carcinoma, which had been very well 
responded to the treatment for years but deteriorates in a short period after the 
cranium metastasis. 
 
 
INTRODUCTION 
Head and neck squamous cell carcinomas (HNSCC) are known as rarely 
causing intracranial metastases. In the last years, HPV related subgroup 
of HNSCC has become a distinct subject of studies. They mostly occur 
at oropharynx. The incidence of HPV-positive HNSCC is increasing. 
Unlike the HPV-negative one, this subgroup does not show a 
relationship with tobacco and alcohol, which are prominent risk factors 
of HNSCC. More favourable results of chemotherapy and radiotherapy 
have been reported in comparison to the HPV-negative variant. The 
more successive local control means better morbidity and survival 
rates. On HPV-positive cases, a better prognosis was reported even on 
lung metastasis, which is the most frequent site of distant recurrence. 
Also, a different pattern of metastasis has been mentioned in recent 
studies (3). On the other hand, the presence of brain metastasis has 
always been accepted as a bad sign regardless of HPV status.  
We present a case of a patient who has one of the most extended 
survival lengths reported in the literature despite unusual multisite 
metastases but deteriorated rapidly due to very aggressive cranium 
metastasis.       
 
CASE REPORT 
Sixty-four years old female patient had submitted to hospital with pain 
on the chest and back in 2013. Examinations revealed metastatic 
Keywords 
metastasis, 
human papilloma virus, 
HPV, 
cranium, 
squamous cell    
 
 
 
 
Corresponding author: 
Gokhan Canaz 
 
Arnavutkoy State Hospital, 
Department of Neurosurgery, 
Istanbul, Turkey 
 
gokhancanaz@gmail.com 
 
 
 
 
Copyright and usage. This is an Open Access 
article, distributed under the terms of the Creative 
Commons Attribution Non–Commercial No 
Derivatives License (https://creativecommons 
.org/licenses/by-nc-nd/4.0/) which permits non-
commercial re-use, distribution, and reproduction 
in any medium, provided the original work is 
unaltered and is properly cited. 
The written permission of the Romanian Society of 
Neurosurgery must be obtained for commercial 
re-use or in order to create a derivative work. 
 
 
ISSN online 2344-4959 
© Romanian Society of 
Neurosurgery 
 
 
 
First published 
June 2020 by 
London Academic Publishing 
www.lapub.co.uk 
 
 354 Gokhan Canaz, Huseyin Canaz, Sabri Aydin 
lymphadenopathies on mediastinum and 
metastases on the lung, liver, and vertebra corpus, 
but the primary tumour had not been found. With 
consecutive periods of chemotherapy (including 
carboplatin, capecitabine, and cisplatin-etoposide) 
and radiotherapy, local control was achieved, and 
the patient has succeeded five years of survival. In 
2018, the patient had multiple enlarged lymph nodes 
in the cervical area. Following the tru-cut biopsy 
results, the pathology report pointed out CD117 
positivity and low metabolic activity despite the 
clinical features. As a result, pathological 
examinations could not suggest a diagnosis. The new 
PET scan revealed multiple mediastinal and 
intraabdominal lymphadenopathies and improved 
uptake in various areas in the gastrointestinal 
system. With chemotherapy and radiotherapy, the 
local cure was succeeded. Other sites also 
responded to the treatment. In November 2018, in 
an examination for head-ache, extensive cranium 
metastasis was spotted. The patient was consulted 
to neurosurgery, and surgery was offered (Fig. 1). 
During the decision period of patient, right 
hemiparesis and headache complaints were 
developed. In concomitant MRIs within three months 
period, significant enlargement was discovered, and 
operation was performed (Fig. 2,3). 
First, question mark skin incision was performed, 
and the tumour was revealed, extruding from the 
calvarium. A large frontoparietal craniotomy flap, 
which was covering the whole tumour and adherent 
dura, was elevated. Because of the cohesiveness, the 
dura was incised and elevated with the tumour. No 
invasion to parenchyma was observed but cerebrum 
was edematous. Because of that after bone-tumour-
dura complex resection, cranioplasty was planned 
for a further time.  
Pathologic examination revealed that the tumour 
was HPV positive oropharyngeal squamous cell 
carcinoma metastasis with strong p16 and 
neuroendocrine marker positivity. Different from the 
previously pathological examination, ki-67 index was 
found to be very high (about %80). Post-op PET scan 
also revealed an oropharyngeal mass with improved 
up-take near the base of the tongue.  
 
DISCUSSION 
HPV positive HNSCC are characterized by a better 
therapeutic response and lower recurrence in 
comparison to HPV negative variant, which means  
 
 
Figure 1.  
 
overall better clinical outcome in terms of survival 
and morbidity (2). Because of this nature of HPV 
positive HNSCC, even in the presence of metastases, 
more direct and curative approaches are preferred 
instead of palliative treatment options. 
Besides the better outcomes, the distant 
metastasis pattern of HPV positive SCC also differs. 
The longer survival lengths, thank to better 
therapeutic results, may contribute to increased 
numbers of distant metastases on HPV positive SCC. 
The most frequent metastasis sites for HNSCC are 
known as lung, liver, and bone (5). In this order, liver 
and bone metastases were reported as much rarer 
than the lung. An increased incidence in bone 
metastases, especially in vertebras, were reported in 
patients with p16 positive tumours lately. The recent 
articles are reporting HPV positive SCC cases with 
multisite metastasis, including unusual sites such as 
long bones, brain, dura, pancreas, and skin (3,4). 
Among the metastasis sites, the brain was accepted 
to have the worst prognosis and defined as “non-
curable”. Brain metastasis frequency on HNSCC was 
mentioned in a few articles as 0.43 – 5.7%. 
The tumour-free episodes in HPV positive SCC are 
reported to be longer than non-HPV variants in 
several studies (2). When the recurrence or first 
metastasis was spotted during follow-ups, patients 
usually have metastasis on more than one site. In 
both HPV + and – tumours, metastases have much 
more aggressive behaviors than their primary 
tumours. Independent from the response of these 
metastases to the treatment, different, unexpected 
new metastases may occur, and the death of 
patients is usually caused by these aggressive new 
tumours. The development time of metastases is 
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approximately two years following the primary 
tumour treatment (4, 5). In a recent study about 
brain metastases of HNSCC, mean time of interval 
between diagnosis of primary and brain metastasis 
was reported as 26 months. Among the eleven 
patients, two longest intervals were 137 and 66 
months, and the latter patient had 65.7 months of 
disease-free time, meaning prognosis of the brain 
metastasis was the decisive factor in patients’ life (1).  
Besides clinical features, HPV positive SCC’s are 
known to be hard to detect on PET and MRI scans. As 
in our case, this mass had not been detected 
previous PET and MRI scans. 
 
CONCLUSION 
Extended patient follow-up times are suggested for 
HPV positive tumours in many papers as a 
conclusion (2, 4). Under these circumstances, we 
think that it would not be wrong to define the length 
of follow-up as "lifelong". Considering positive 
features of HPV-positivity, with further analysis of 
metastasis pattern of HPV positive HNSCC and with 
the developments of neurosurgical oncology, much 
longer survivability can be achieved in this patient 
group. 
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The patient has consented to the submission of the case report 
for submission to the journal. 
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